We claim:

1. ~~A method for the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia comprising administering~~ Use of an effective dose of masupirdine, or a pharmaceutically acceptable salt thereof in combination with ~~and~~ an acetylcholinesterase inhibitor or NMDA receptor antagonist, in the manufacture of a medicament for the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine or a pharmaceutically acceptable salt thereof; and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

2. The ~~method~~ use of claim 1, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

3. The ~~method~~ use of claim 2~~1~~, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

4. The ~~method~~ use of claim 2~~1~~ or claim 3, wherein the NMDA receptor antagonist is memantine hydrochloride.

5. The ~~method~~ use as claimed in any one of claims 2 to 4~~1~~, wherein ~~the treatment comprising administering an~~the effective dose of masupirdine dimesylate monohydrate and donepezil hydrochloride, if present, is to be administered to the patient.

6. The ~~method~~ use as claimed in any one of claims 2 to ~~4~~1, wherein ~~the treatment comprising administering an~~the effective dose of masupirdine dimesylate monohydrate and memantine hydrochloride, if present, is to be administered to the patient.

7. The ~~method~~ use of any one of claims 1 to 6, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia.

8. The ~~method~~ use of claim 1, wherein the agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with Alzheimer's disease dementia.

9. The ~~method~~ use of claim 1, wherein the agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with Parkinson's disease dementia.

10. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 25 mg to 125 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

11. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 25 mg to 75 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

12. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 75 mg to 125 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

13. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 50 mg or 100 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

14. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 5 mg to 25 mg of donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

15. The ~~method~~ use of claim 1, wherein ~~the treatment comprises administering to the patient~~ 5 mg to 30 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

~~16. A pharmaceutical composition, comprising an effective amount of masupirdine or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor or NMDA receptor antagonist as claimed in claim 1 for use in the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia.~~

~~17. The pharmaceutical composition for use according to claim 16, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia.~~

~~18. The pharmaceutical composition for use according to claim 16, wherein the agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in patient with Alzheimer's disease dementia.~~

~~19. The pharmaceutical composition for use according to claim 16, wherein the agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant~~

~~motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with Parkinson's disease dementia.~~

16~~20~~. The ~~pharmaceutical composition for~~ use of ~~according to~~ claim 1~~6~~, wherein the ~~composition~~ effective dose is to be administered to the patient by oral~~, nasal, local, or parenteral~~ routes.

17. The use of claim 1, wherein the effective dose is to be administered to the patient by nasal routes.

18. The use of claim 1, wherein the effective dose is to be administered to the patient by local routes.

19. The use of claim 1, wherein the effective dose is to be administered to the patient by parenteral routes.

20~~21~~. The ~~pharmaceutical composition for~~ use of ~~according to~~ claim 1~~6~~, wherein the effective dose ~~composition~~ is to be administered to the patient one to three times per day, one to three times per week, or one to three times per month.